Aadi Bioscience Inc (AADI) PT Lowered to $5 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AADI Hot Sheet
Price: $2.05 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Piper Sandler analyst Joseph Catanzaro lowered the price target on Aadi Bioscience Inc (NASDAQ: AADI) to $5.00 (from $30.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK304 at Goldman Sachs
- Avis Budget Group (CAR) PT Lowered to $125 at Susquehanna
- Kraft Heinz Company (KHC) PT Raised to $24 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
